AU1992592A - Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors - Google Patents

Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors

Info

Publication number
AU1992592A
AU1992592A AU19925/92A AU1992592A AU1992592A AU 1992592 A AU1992592 A AU 1992592A AU 19925/92 A AU19925/92 A AU 19925/92A AU 1992592 A AU1992592 A AU 1992592A AU 1992592 A AU1992592 A AU 1992592A
Authority
AU
Australia
Prior art keywords
drug
treatment
type
monoamine oxidase
withdrawal symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU19925/92A
Inventor
George W. Belenduik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Supernus Pharmaceuticals Inc
Original Assignee
Supernus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US70508591A priority Critical
Priority to US705085 priority
Application filed by Supernus Pharmaceuticals Inc filed Critical Supernus Pharmaceuticals Inc
Publication of AU1992592A publication Critical patent/AU1992592A/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
AU19925/92A 1991-05-24 1992-05-04 Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors Abandoned AU1992592A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US70508591A true 1991-05-24 1991-05-24
US705085 1991-05-24

Publications (1)

Publication Number Publication Date
AU1992592A true AU1992592A (en) 1993-01-08

Family

ID=24831978

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19925/92A Abandoned AU1992592A (en) 1991-05-24 1992-05-04 Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors

Country Status (2)

Country Link
AU (1) AU1992592A (en)
WO (1) WO1992021333A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713087B1 (en) * 1993-11-30 1996-02-23 Saurat Jean Hilaire Use of selegiline and its derivatives for the preparation of a medicament for the treatment of psoriasis.
US6319954B1 (en) * 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
US6299901B1 (en) 1995-01-13 2001-10-09 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
JPH10513455A (en) * 1995-02-10 1998-12-22 ザ ユニバーシティ オブ トロント イノベーションズ ファウンデーション Deprenyl compounds for the treatment of glaucoma
WO1996040085A2 (en) 1995-06-07 1996-12-19 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
DE19746191C2 (en) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts A method for application of an active substance-containing patch for the control or relief of addiction
US6210705B1 (en) * 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US7083808B2 (en) 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6280763B1 (en) 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
AT427745T (en) * 2001-11-05 2009-04-15 Krele Pharmaceuticals Llc Compositions and methods for the erhíhung compliance with therapies using aldehyde dehydrogenase inhibitors, and for treatment of alkoholsmus
AU2003250106B2 (en) 2002-07-18 2009-11-26 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
JP5930573B2 (en) 2007-03-01 2016-06-15 プロビオドルグ エージー A new use of glutaminyl cyclase inhibitors
EP2433626B1 (en) 2003-11-25 2015-11-04 Technion Research & Development Foundation Ltd. Compositions and methods for treatment of cardiovascular disorders and diseases
US8263655B2 (en) 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
DE102006038719A1 (en) 2006-08-18 2008-02-21 Tesa Ag Adhesive strip for moisture insensitive repositionable adhesive bonds
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US9943489B2 (en) 2010-02-03 2018-04-17 Pharmatwob Ltd. Extended release formulations of rasagiline and uses thereof
ES2586231T3 (en) 2010-03-03 2016-10-13 Probiodrug Ag Glutaminyl cyclase inhibitors
CN102791704B (en) 2010-03-10 2015-11-25 前体生物药物股份公司 Glutaminyl cyclase (qc, ec 2.3.2.5) heterocyclic inhibitors
JP5945532B2 (en) 2010-04-21 2016-07-05 プロビオドルグ エージー Benzimidazole derivatives as inhibitors of glutaminyl cyclase
JP6355921B2 (en) 2010-09-01 2018-07-11 トニックス ファーマスーティカルズ,インコーポレイテッドTONIX Pharmaceuticals,Inc. The treatment of cocaine addiction
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
US9937144B2 (en) 2013-01-30 2018-04-10 The Johns Hopkins University Treatment of drug abuse by preventing GAPDH nitrosylation
CA3018328A1 (en) 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase

Also Published As

Publication number Publication date
WO1992021333A3 (en) 1993-01-07
WO1992021333A2 (en) 1992-12-10

Similar Documents

Publication Publication Date Title
AU623599B2 (en) Avirulent microbes, incapable of producing functional adenylate cyclase and cyclic amp
AU636521B2 (en) Inhibitors and substrates of thrombin
AU642020B2 (en) Internal tissue medication permeating apparatus and method
AU657940B2 (en) A method and a removable device which can be used for the self-administered treatment of urinary tract infections or other disorders and as a urethral plug
AU611704B2 (en) Oral sustained release acetaminophen formulation and process
AU682896B2 (en) Drug delivery PTCA catheter and method
AP564A (en) "Polymer coated tablet comprising amoxycillin and clavulanate."
AU701623C (en) Method of inducing and maintaining neuronal cells
TW457242B (en) Thienopyrimidines
AU698403B2 (en) Method of monitoring patient compliance with medications prescriptions
AU649447B2 (en) Production of enzymes in seeds and their use
AU634532B2 (en) Pre-slit injection site and tapered cannula
EG20095A (en) Medicament injectors and methods
AU674894C (en) Treatment of conditions and disease
AU640422B2 (en) Stent and catheter for the introduction of the stent
AU591561B2 (en) Catheter retention device and method
AU646230B2 (en) Pharmaceutical compositions and methods for treating the symptoms of overindulgence
AU646232B2 (en) Effervescent dosage form and method of administering same
HK1041203A1 (en) Pharmaceutical composition comprising pioglitazone and glimepiride for use in treatment of diabetes
AU9028491A (en) Iontophoretic drug delivery electrode and method of hydrating the same
AU1085892A (en) Torquable catheter and method
EP0666753A4 (en) Method for the treatment of the complications and pathology of diabetes.
HK1007490A1 (en) Drug delivery system and method of making the same
AU1964888A (en) Monocoque device for disassembly and hermetic storage of used hypodermic needles
EP0200351A3 (en) Liquid ethylene-type random copolymer, process for production thereof, and use thereof